Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.A phase II trial evaluating CombinatoRx' drug candidate, CRx-102, in patients with osteoarthritis of the hand, has produced positive preliminary results.
Subscribe to our email newsletter
The study met its primary endpoint of improvement in the Auscan visual analogue pain scale, a standardized measure of pain. The data show that there was a statistically significant 33% improvement in pain in patients receiving CRx-102, compared with a 10% improvement in patients receiving placebo.
CRx-102 was generally well tolerated and there were no serious adverse events reported. The most common adverse events observed with CRx-102 were headache and nausea, known side effects of one of the two components.
“The preliminary results from this first phase IIa trial of CRx-102 give a strong indication of efficacy in hand osteoarthritis with a good safety profile,” said Dr Jan Lessem, chief medical officer of CombinatoRx.
CRx-102 is currently under study in two further phase II clinical trials in patients with rheumatoid arthritis and in a systemic inflammatory disease model, chronic adult periodontitis.